Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
41 studies found for:    Eribulin Mesylate | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of Eribulin in Children With Cancer to Determine Safety
Conditions: Pediatric Cancer;   Solid Tumors;   Lymphoma
Intervention: Drug: Eribulin mesylate
2 Recruiting Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: Eribulin mesylate;   Other: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20);   Other: Biologic: PEGylated recombinant human hyaluronidase
3 Recruiting PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
Conditions: Metastatic Breast Cancer;   Toxicity;   Neurotoxicity;   Drug Toxicity;   Adverse Drug Event
Intervention: Drug: ERIBULIN MESYLATE
4 Recruiting Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Conditions: Metastatic Breast Cancer;   Brain Metastases
Interventions: Drug: Eribulin Mesylate;   Device: MRI;   Drug: Pre-Medication: Zofran;   Drug: Pre-Medication: Decadron
5 Recruiting This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas.
Conditions: Pediatrics;   Solid Tumors
Intervention: Drug: Eribulin Mesilate
6 Recruiting Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
Conditions: Recurrent Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Drug: eribulin mesylate
7 Recruiting Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
Conditions: Breast Cancer;   Adenocarcinoma
Intervention: Drug: Eribulin mesilate
8 Recruiting A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Eribulin Mesylate;   Drug: Pembrolizumab
9 Recruiting Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
Conditions: Metastatic Malignant Neoplasm in the Adult Brain;   Primary Brain Tumor
Interventions: Procedure: Therapeutic Conventional Surgery;   Procedure: Biopsy;   Drug: Eribulin Mesylate;   Procedure: Microdialysis;   Other: Pharmacological Study
10 Recruiting Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Conditions: Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Eribulin Mesylate;   Other: Laboratory Biomarker Analysis
11 Recruiting Eribulin and Lenvatinib in Advanced Solid Tumors
Conditions: Cancer;   Solid Tumor
Interventions: Drug: Eribulin;   Drug: Lenvatinib
12 Recruiting Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397;   Drug: Eribulin
13 Recruiting PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
Condition: Metastatic Breast Cancer
Interventions: Drug: PQR309;   Drug: Eribulin
14 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Recruiting Halaven Post-Marketing Surveillance (PMS)
Condition: Breast Cancer
Intervention:
16 Recruiting Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Condition: Locally Advanced or Metastatic Breast Cancer
Intervention: Drug: Eribulin
17 Recruiting Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors
Condition: Solid Tumor
Intervention: Drug: Irinotecan + Eribulin
18 Recruiting A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Condition: Sarcoma, Soft Tissue
Intervention: Drug: Eribulin mesylate
19 Recruiting Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Conditions: Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
20 Recruiting A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
Conditions: Relapsed Solid Tumors;   Refractory Solid Tumors
Interventions: Drug: Eribulin;   Drug: Irinotecan;   Other: Cefixime

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.